Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

Stroke, Acute, Stroke Ischemic Clinical Trial

— TASTEa  

Official title:

Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04071613
• Other study ID #: 2018.043
• Status: Completed
• Phase: Phase 2
• Start date: June 20, 2019
• Est. completion date: November 16, 2021

Study information

• Verified date: October 2021
• Source: Melbourne Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ischemic stroke is a major health burden globally and in Australia. Treatment for ischemic stroke is time critical and is significantly more effective if administered within the first 90 minutes of symptom onset. This clinical trial will identify if early administration of oral thrombolytic agent, tenecteplase prior to hospital can improve outcomes from stroke, and reduce costs compared to standard care of IV alteplase in hospital

Description:

Currently, alteplase is the standard clot-dissolving therapy for ischemic stroke, however this treatment is only effective in 30-45% of patients. Importantly, treatment of ischemic stroke is more effective when given within 90 minutes of stroke onset. Means of treating patients earlier with more effective therapies are needed. Ischemic stroke is a major public health problem, for which effective and accessible drug therapies remain limited. Current management of acute ischemic stroke includes treatment with a solution called alteplase, which dissolves clots in a cerebral artery. The treatment effect of alteplase is much greater if given within 90 minutes of stroke onset. As a result, there has been a significant push to take stroke care to the patient in the form of the Mobile Stroke Unit (MSU). The MSU is the first designed as a CT-capable ambulance that allows assessment and treatment of stroke patients in the pre-hospital setting. In the proposed research project, we will undertake a clinical trail investigating the effectiveness of a new thrombolytic agent in the MSU, tenecteplase. Tenecteplase has been shown to be significantly more effective at improving stroke survivor's recovery and opening blocked blood vessels than alteplase in the hospital setting. However, it is unknown if earlier administration of tenecteplase is more effective than early administration of alteplase. The tested agent, tenecteplase, is cheaper, easier to administer (no time-consuming infusions required) and more practical for an ambulance delivered therapy than the current standard of care alteplase. If tenecteplase results in better clinical outcomes in addition to these practical advantages, there is significant scope for improved patient outcomes and cost savings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 104
• Est. completion date: November 16, 2021
• Est. primary completion date: November 16, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients being attended by the mobile stroke unit with an acute ischemic stroke eligible for thrombolysis using standard clinical and CT criteria.

2. Patient's age is =18 years

3. Premorbid mRS <4

Exclusion Criteria:

1. Intracranial hemorrhage (ICH) or other diagnosis (e.g. tumor) identified by CT on the MSU

2. Hypodensity in >1/3 MCA territory or equivalent proportion of ACA or PCA territory on non-contrast CT on MSU

3. Pre-stroke mRS score of > 3 (indicating significant previous disability)

4. Any terminal illness such that patient would not be expected to survive more than 1 year

5. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.

6. Pregnant women.

7. Rapidly improving symptoms.

Related Conditions & MeSH terms

• Stroke
• Stroke, Acute, Stroke Ischemic

Intervention

Drug:
• Tenecteplase
Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
• Intravenous tissue plasminogen activator (tPA)
Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset

Locations

Country	Name	City	State
Australia	Alfred Hopsital	Melbourne
Australia	Eastern Health	Melbourne	Victoria
Australia	Monash Health	Melbourne
Australia	Royal Melbourne Hospital	Melbourne	Victoria
Australia	Western Hospital	Melbourne	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
Melbourne Health

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perfusion lesion on CTP	The volume of the perfusion lesion on CTP performed on arrival at the receiving hospital, adjusted for pre-treatment NIHSS and time from initiation of treatment to CTP.	Within 2hrs of treatment
Secondary	Infarct core growth between baseline CTP and 24 hour MRI.		24 hrs
Secondary	Percent reperfusion between baseline CTP and 24 hour perfusion imaging (MRI)		24 hrs
Secondary	Reduction in NIHSS between pre-treatment score and score on ED arrival, adjusted for pre-treatment NIHSS and time from initiation of treatment to ED NIHSS score		2 hrs
Secondary	Reduction in NIHSS between pre-treatment score and score at 24 hours post treatment, adjusted for pre-treatment NIHSS		24 hrs
Secondary	Modified Rankin Scale (mRS) at 3 months - ordinal analysis adjusted for baseline NIHSS and age		3 months
Secondary	mRS 0-2 or no change from baseline at 3 months adjusted for baseline NIHSS and age		3 months
Secondary	Proportion of patients where thrombolytic medication is initiated within 5 minutes of completion of CT on the MSU.		24 hrs
Secondary	Time from completion of CT on the MSU to initiation of thrombolysis (CT to needle time)		2 hrs
Secondary	mRS 5-6 at 3 months adjusted for baseline NIHSS and age		3 months
Secondary	Death due to any cause adjusted for baseline NIHSS and age		During time on study up to 3 months
Secondary	Any parenchymal haematoma		During time on study up to 3 months
Secondary	ymptomatic intracranial hemorrhage (sICH)		During time on study up to 3 months